Navigation Links
Asmacure Ltee Issued Patent to Govern Composition-of-Matter for its Nicotinic Receptor Technology in the U.S.
Date:10/25/2011

QUEBEC CITY, Oct. 25, 2011 /PRNewswire/ -- Asmacure Ltee, a clinical-stage biopharmaceutical company focused on the development of nicotinic receptor agonists for the treatment of asthma and other inflammatory diseases, announced today that it has been issued U.S. patent No. 8,039,459 from the United States Patent & Trademark Office (USPTO) entitled "Nicotinic Receptor Agonists for the Treatment of Inflammatory Diseases."  The first patent of this series in the USPTO comprises compounds and pharmaceutical composition claims.

"The issuance of these patents in the U.S. and Japan are important developments for the strong global intellectual property estate for our lead compound, ASM-024," said Mr. Martin Driscoll, CEO of Asmacure. "This important expansion of the patent protection for ASM-024 is another milestone in the development of our proprietary new mechanism for the treatment of asthma and other respiratory inflammatory diseases."

The nicotinic receptor agonist compounds developed for the treatment of pulmonary inflammatory diseases were discovered at the Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Quebec, a research center affiliated with Universite Laval. Asmacure has an exclusive license from Universite Laval to develop and commercialize any product derived from this technology.

On July 15, 2011, the Japan Patent Office issued the corresponding Japanese patent No. 4783787.  The claims within the patent are directed to compounds as well as pharmaceutical compositions for treating or preventing pulmonary inflammatory diseases.

About Asmacure

Asmacure Ltee is a clinical-stage biopharmaceutical company focused on the development of nicotinic receptor agonists for the treatment of asthma and other inflammatory diseases. The company's lead compound, ASM-024, is a novel molecular entity currently in clinical development for the treatment of asthma. ASM-024 utilizes Asmacure's proprietary technology comprised of nicotinic acetylcholine receptor agonists and is the first nicotinic receptor agonist in the clinic for this indication.  Phase II proof-of-concept studies are ongoing to assess the anti-inflammatory, bronchodilating and bronchoprotective properties of ASM-024 administered by inhalation.  

Asmacure is a privately held company located in Quebec City, Canada. The major investors in Asmacure include Domain Associates, Fonds Bio-Innovation and Innovatech Quebec. For more information visit www.asmacure.com

Media Contacts:
Tiberend Strategic Advisors, Inc.
(212) 827-0020
Andrew Mielach, amielach@tiberend.com
or
Claire Sojda, csojda@tiberend.com


'/>"/>
SOURCE Asmacure Ltee
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Asmacure Ltee to Present at the 2011 BIO Business Forum During the Annual BIO International Convention
2. Vantage Health Announces That All of Its Required Tanzanian Registrations, Permits and Licenses Have Been Formally Issued, Simultaneous With Official Notification That Its Application for Phase One Evaluation of Its HIV Screening Test Kits Has Been
3. Curemark Issued Patent for the Diagnosis of Parkinsons Disease
4. Urgent Call Is Issued for More Local Doctors and Nurses for Mondays Free Health Clinic
5. U.S. Patent for Leatt Neck Brace System Issued
6. China Medical Technologies Announces the First Inclusion of FISH Tests for Diagnosis of Certain Hematological Malignancies in the Clinical Guidelines Issued by the MOH
7. PRA Experts Pulmonary Function Textbook Reissued
8. Voluntary Worldwide Field Correction Issued for the S98/98XT, CS100/CS100i and CS300 Intra-Aortic Balloon Pumps
9. Applied Medical Sues Covidien, Asserting Recently Issued Universal Seal Trocar Patent
10. Landmark Patents Issued for ViewRay Technology
11. Two New U.S. Patents Issued to Dyadic International
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 19, 2017 Pfizer joins ... Milner Therapeutics Consortium   Major research ... Cambridge   The Milner Therapeutics ... ) as a partner to the Milner Therapeutics Consortium. ... the efficient transfer of materials between industry and academia ...
(Date:1/19/2017)... The global  pacemaker market  is expected to reach USD 12.3 billion by ... prevalence of cardiac conditions coupled with the availability of medical coverage is a ... in these devices are supporting the expansion of this vertical. ... ... View Research Logo ...
(Date:1/19/2017)... 18, 2017 The Global Therapy Partnering Terms ... to partnering deals and agreements entered into by the ... deals - Top deals by value - Deals listed ... type The report provides understanding and access to ... world,s leading healthcare companies. The report provides an ...
Breaking Medicine Technology:
(Date:1/20/2017)... , ... January 20, 2017 , ... “The Angel”: ... Lord has set out for each of his children. “The Angel” is the creation ... of Music in New York City, and impassioned writer. , When asked of her ...
(Date:1/20/2017)... ... ... beautiful and enchanting tale that teaches children the true meaning of Christmas. “Journey to Christmas” ... and a devoted woman of faith. , “Becoming a parent changes you. In my ... mind for years, but actually doing it might have been a while in coming if ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... On-demand E-learning system for Clinical and Regulatory education for Physicians, Physician Advisors, ... Aerolib`s successful education methodology of Disease Specific Documentation Improvement. , The Aerolib ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... for tech innovators, engineers, and scientists from around the world, announces the launch ... users a quick and easy portal to research breakthroughs and trending news, vital ...
(Date:1/19/2017)... ... January 19, 2017 , ... Catalent Pharma Solutions, the ... and consumer health products, today announced that it will be co-hosting a workshop ... excipients and drug delivery solutions to health industries worldwide. The one day event ...
Breaking Medicine News(10 mins):